BENCHMARKING THE IMPACT OF HTA ON NEW MEDICINES DEVELOPMENT AND COVERAGE DECISION MAKING

被引：1
|
作者：
Wang, T. [1 ]
机构：
[1] CIRS, London, England
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.478
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP84
引用
收藏
页码：A798 / A798
页数：1
相关论文
共 50 条
  • [1] IMPACT OF TOLERABILITY PROFILES ON HTA DECISION MAKING IN ONCOLOGY
    Kreeftmeijer, J.
    Ryan, J.
    Van Engen, A.
    Heemstra, L.
    VALUE IN HEALTH, 2015, 18 (03) : A220 - A220
  • [2] IMPLEMETATION OF HTA IN DECISION-MAKING PROCESS OF SELECTING ESSENTIAL MEDICINES IN UKRAINE
    Oleshchuk, O.
    Vashchenko, O.
    Piniazhko, O.
    Topachevskyi, O.
    Zinchenko, Z.
    VALUE IN HEALTH, 2022, 25 (01) : S173 - S174
  • [3] INCORPORATING HEALTH INEQUALITIES (HIS) CONSIDERATIONS INTO UNITED KINGDOM (UK) HTA DECISION MAKING AND THE IMPACT ON RARE DISEASE MEDICINES
    Patel, A.
    Guest, S.
    Holdgate, O.
    Rouse, P.
    Furby, H.
    Bradley, S.
    VALUE IN HEALTH, 2023, 26 (12) : S366 - S366
  • [4] SCHIZOPHRENIA AND HTA DECISION MAKING
    Chawla, T.
    Albero, Izquierdo R.
    Rube, M.
    Oshinowo, B.
    VALUE IN HEALTH, 2020, 23 : S590 - S590
  • [5] THE ROLE OF HTA AGENCY IN DRUG REIMBURSEMENT DECISION-MAKING PROCESS IN POLAND (HTA IMPACT)
    Kolasa, K.
    VALUE IN HEALTH, 2009, 12 (07) : A251 - A251
  • [6] HTA and National Immunisation Program: an overview of competent bodies and of the impact of HTA on the decision-making process
    Ricciardi, W.
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2022, 32
  • [7] PERSPECTIVES OF IMPLEMENTATION AND DEVELOPMENT OF HTA SYSTEM IN UKRAINE: USE IN DECISION MAKING
    Zaliska, O.
    Piniazhko, O.
    Kosyachenko, K.
    Tolubaiev, V
    VALUE IN HEALTH, 2016, 19 (03) : A286 - A287
  • [8] THE EVOLUTION OF HTA AS A COVERAGE DECISION-MAKING TOOL IN THE MIDDLE EAST AND NORTH AFRICA REGION
    Chui, C.
    McGee, M.
    Rodrigues, T.
    Lockwood, C.
    Ando, G.
    VALUE IN HEALTH, 2015, 18 (07) : A550 - A550
  • [9] Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
    Bloem, Lourens T.
    Vreman, Rick A.
    Peeters, Niels W. L.
    Hoekman, Jarno
    van Der Elst, Menno E.
    Leufkens, Hubert G. M.
    Klungel, Olaf H.
    Goettsch, Wim G.
    Mantel-Teeuwisse, Aukje K.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (04): : 1566 - 1577
  • [10] TIME TO HTA DECISION FOR INTERNATIONALISED MEDICINES IN AUSTRALIA, CANADA AND EUROPE
    Cai, J.
    McAuslane, N.
    Liberti, L.
    VALUE IN HEALTH, 2018, 21 : S198 - S198
12345